Church & Dwight Co., Inc. v. Mayer Laboratories, Inc.

868 F. Supp. 2d 876, 2012 U.S. Dist. LEXIS 51770, 2012 WL 1231801
CourtDistrict Court, N.D. California
DecidedApril 12, 2012
DocketNo. C-10-4429 EMC
StatusPublished
Cited by2 cases

This text of 868 F. Supp. 2d 876 (Church & Dwight Co., Inc. v. Mayer Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Church & Dwight Co., Inc. v. Mayer Laboratories, Inc., 868 F. Supp. 2d 876, 2012 U.S. Dist. LEXIS 51770, 2012 WL 1231801 (N.D. Cal. 2012).

Opinion

[884]*884ORDER GRANTING IN PART AND DENYING IN PART PLAINTIFF’S MOTION FOR SUMMARY JUDGMENT

EDWARD M. CHEN, District Judge.

Plaintiff/Counterdefendant Church & Dwight, Inc. (“C & D”), the maker of Trojan brand condoms, moves for summary judgment on Defendant/Counter-claimant Mayer Labs, Inc.’s (“Mayer’s”) counterclaims. Docket No. 187, 198 (redacted version). Mayer is the maker of Kimono brand condoms. The parties’ primary dispute surrounds C & D’s use of planogram1 agreements with condom retailers, whereby C & D offers a percentage rebate off its wholesale price in exchange for a retailer’s commitment to devote a certain percentage of the condom shelf space to C & D products. Mayer alleges that C & D’s planogram rebate (“POG”) program operates to foreclose competition from vital retail display space and hence sales. Mayer also alleges that C & D has engaged in other anticompetitive conduct, including abusing its position as category captain for certain retailers to exclude its rivals from, or at least disadvantage them in, the condom retail market. Based on this and other alleged conduct, Mayer brought twelve counterclaims against C & D for purported violations §§ 1 and 2 of the Sherman Act, the Cartwright Act, the Lanham Act, and California unfair competition laws, as well as tort claims for tortious interference with contract and economic relations.

The parties have engaged in over three years of hotly contested litigation. This Court previously denied C & D’s motion to dismiss Mayer’s counterclaims finding that Mayer’s complaint raised viable claims of anticompetitive conduct potentially violative of the Sherman Act. See Docket No. 105; Church & Dwight Co., Inc. v. Mayer Laboratories, Inc., C-10-4029 EMC, 2011 WL 1225912 (N.D.Cal. Apr. 1, 2011). The parties have conducted extensive discovery of over 15 million pages of documents and dozens of depositions. Reply at 1. Documents submitted in conjunction with the parties’ summary judgment briefing total over four thousand pages.

Despite this voluminous record, Mayer has been unable to proffer any direct, admissible evidence of retailers switching or removing rival condom brands from their shelves as a result of any coercive effect of C & D’s planogram program. Nor has Mayer submitted any admissible evidence that C & D misused its category captain positions to the detriment of its rivals. Surprisingly, Mayer failed to take the deposition of — or obtain other direct evidence from — -any retailer’s employees or other third parties who might have testified to the supposed coercive, anticompetitive effect of C & D’s conduct. Indeed, the only direct (and unrebutted) evidence from third party retailers indicates just the opposite: that the planogram program has little, if any, effect on retailers’ shelf space allocations, and that C & D had no undue influence over retailers’ decisions as category captain. Without any such direct evidence, the Court is left largely with Mayer’s (and its experts’) own theory based largely on a rough correlation between C & D’s moderately increasing market share and Mayer’s moderately decreasing market share.

Accordingly, having considered the parties’ briefs, accompanying submissions, oral argument, and all evidence of record, the Court DENIES the motion for sum[885]*885mary judgment as to tortious interference with contract, and GRANTS the motion as to all other claims.

I. FACTUAL & PROCEDURAL BACKGROUND

The evidence submitted by the parties reflects as follows. Where there are factual disputes, they are so noted.

A. The Parties

Mayer Labs markets, distributes and sells latex male condoms. Second Amended Counterclaim (“SAC”) ¶¶ 15, 19. Mayer’s business involves the marketing and sale of, inter alia, its Kimono brand of ultra-thin latex condoms. Id. ¶ 15. Kimono condoms have a retail market share in the United States of less than one-half of 1%. Silberman Report Ex. 1. Between 2001 and 2007, Mayer’s market share increased from .31 % to .46%. Id. Starting in 2008, market share decreased to a low of .27% in 2009, and remained at .29% in 2010. Id. Its 2010 market share corresponds to annual revenue of $819,876.

Counterdefendant C & D manufactures and distributes, inter alia, Trojan and other brand-name condoms. C & D branded condoms now account for over 75% of all retail condom sales in the United States. Silberman Report Ex. 1. C & D’s market share has steadily increased from its 2001 share of 67.2% (or $143,630,000 in annual revenues) to its 2010 share of 75.43% (or $210,086,934 in annual revenues). Id. Its market share has been over 50% since 1985. Wright Report Attachment 4.

The next largest condom brand is Durex, marketed by Reckitt Benckiser Group, with approximately 14% of sales as of 2010. Id. Attachment 8. Durex has maintained a steady market share of 14-15% since at least 2004. Id. The third largest brand is Lifestyles, marketed by Ansell Healthcare, with just under 10% market share as of 2012. Id. Its market share has ranged from a high of over 12% in 2004 to a low of 8% in 2008. Id. Together, condoms sold by the three largest companies account for over 99% of the nationwide market. Wright Report Attachment 8. Globally, Durex/Reckitt is the largest condom manufacturer with a 34% share of the global market, Lifestyles/Ansell is second with a 17% share, and Trojan/C & D is third with 11%. Wright Report at 35.

B. The U.S. Condom Industry

The vast majority of condoms in the United States are sold in one of three channels. First, the food, drug, and mass merchandiser channel, absent Wal-Mart (“FDMx”),2 accounts for about 49% of the unit sales in the retail market. Wright Report Attachment 1. Second, Wal-Mart alone accounts for 33%. Id. Third, convenience stores (“c-stores”) account for 14.9%. Id. The remaining sales occur in club stores (e.g., Costco) and dollar stores (e.g., Dollar General). Id.

These channels differ somewhat in their pricing and sales structure. For example, drug stores tend to carry the largest variety of condom brands, and their retail prices are on average twice as high as the mass merchandiser channel. Martineau Federal Trade Commission (“FTC”) Depo., Mayer Ex. 1, at 38-40. C-stores tend to carry only one or two brands of condoms in three-unit packs due to limited shelf-space, and typically seek exclusive contract bids from manufacturers. Baseman Report at 18; Wright Report at 4. Club stores and dollar stores may also use [886]*886exclusive contracts, and club stores tend to sell bulk packs only. Wright Report 55-56.

The parties dispute the extent to which there are barriers to entry in the retail condom market. Mayer claims that there are considerable barriers, including costs of FDA and state regulatory approval and compliance, production mínimums, and retailer program participation fees. See, e.g., Baseman Report at 22-23; Wedel Decl. ¶¶ 15-19; Mayer Ex. 61. C & D argues that the FDA approval process is not overly rigorous and that the barriers to entry are not substantial. See Wright FTC Report at 14.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Feitelson v. Google Inc.
80 F. Supp. 3d 1019 (N.D. California, 2015)
Jones v. Walgreen Co.
679 F.3d 9 (First Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
868 F. Supp. 2d 876, 2012 U.S. Dist. LEXIS 51770, 2012 WL 1231801, Counsel Stack Legal Research, https://law.counselstack.com/opinion/church-dwight-co-inc-v-mayer-laboratories-inc-cand-2012.